Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series
Multiple myeloma (MM) is a neoplastic proliferation of plasma cells in the bone marrow, accounting for 1% of all cancers and ∼ 10% of all hematologic malignancies.1 MM diagnosis requires ≥ 10% clonal bone marrow plasma cells or a biopsy-proven plasmacytoma plus evidence of one or more MM-defining events: CRAB features related to the plasma cell disorder (ie, hypercalcemia [C], renal failure [R], anemia [A], or lytic bone lesions [B]), bone marrow clonal plasmacytosis ≥ 60%, serum involved/uninvolved free light chain (FLC) ratio ≥ 100 (provided involved FLC is ≥ 100 mg/L), or> 1 focal lesion on magnetic resonance imaging.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Hila Magen, Mika Geva, Yulia Volchik, Abraham Avigdor, Arnon Nagler Tags: Case Report Source Type: research
More News: Anemia | Bone Marrow Aspiration and Biopsy | Cancer | Cancer & Oncology | Dexamethasone | Hematology | Leukemia | Lymphoma | MRI Scan | Myeloma | Plasmacytoma | Renal Failure | Velcade